CTIC · Cti Biopharma Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $3.35M | $25.15M | $25.15M |
| Cost of Revenue | $0 | - | - | - | $364.0K | - |
| Gross Profit | $0 | - | - | - | $24.78M | - |
| R&D | $36.90M | $39.14M | $25.94M | $24.11M | $36.47M | $32.87M |
| SG&A | $84.83M | $56.20M | $17.63M | $19.16M | $21.18M | $31.43M |
| Total Operating Expenses | $133.75M | $95.33M | $47.77M | $44.06M | $59.19M | $64.67M |
| D&A | $1.95M | $526.0K | $532.0K | $546.0K | $593.0K | $717.0K |
| Operating Income | ($79.80M) | ($95.33M) | ($47.77M) | ($40.71M) | ($32.90M) | ($39.52M) |
| Interest Expense | $13.14M | $2.42M | $511.0K | $1.00M | $1.21M | $1.87M |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($92.99M) | ($97.91M) | ($52.45M) | ($40.02M) | ($29.32M) | ($40.67M) |
| EPS - Basic | ($0.81) | ($0.74) | - | - | - | - |
| EPS - Diluted | ($0.81) | ($0.74) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.42M | $65.45M | $40.39M | $31.14M | $36.44M | $27.22M |
| Accounts Receivable | $15.39M | - | - | - | - | $4.0K |
| Inventory | $733.0K | - | - | - | - | $550.0K |
| Accounts Payable | $2.01M | $3.89M | $1.64M | $0 | $4.50M | $2.59M |
| Current Assets | $99.40M | $68.38M | $54.33M | $35.58M | $82.49M | $46.92M |
| Total Assets | $125.92M | $72.43M | $58.24M | $46.28M | $89.83M | $54.89M |
| Current Liabilities | $81.13M | $66.65M | $17.04M | $18.49M | $23.05M | $19.26M |
| Long-term Debt | $47.94M | $47.38M | $0 | $4.46M | $9.27M | $13.57M |
| Total Liabilities | $143.50M | $68.67M | $18.21M | $28.35M | $36.89M | $38.80M |
| Stockholders' Equity | ($17.58M) | $3.77M | $40.03M | $23.69M | $58.69M | $21.81M |
| Retained Earnings | ($2.52B) | ($2.43B) | ($2.33B) | ($2.26B) | ($2.22B) | ($2.20B) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($81.19M) | ($84.89M) | ($42.20M) | ($27.82M) | ($39.82M) | ($76.68M) |
| Investing Cash Flow | ($73.85M) | $12.00M | ($9.62M) | $28.13M | ($30.49M) | ($137.0K) |
| Financing Cash Flow | $120.02M | $97.94M | $61.07M | ($5.61M) | $63.49M | ($7.37M) |
| CapEx | - | $0 | $17.0K | $0 | $33.0K | $49.0K |
| Free Cash Flow | - | ($84.89M) | ($42.22M) | ($27.82M) | ($39.86M) | ($76.73M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | 98.6% | - |
| Operating margin | - | - | - | -1217.1% | -130.8% | -157.2% |
| EBITDA margin | - | - | - | -1200.7% | -128.5% | -154.3% |
| Net margin | - | - | - | -1196.4% | -116.6% | -161.7% |
| Free cash flow margin | - | - | - | -831.7% | -158.5% | -305.1% |
| FCF / Net income | - | 0.87 | 0.80 | 0.70 | 1.36 | 1.89 |
| R&D / Revenue | - | - | - | 720.7% | 145.0% | 130.7% |
| SG&A / Revenue | - | - | - | 572.6% | 84.2% | 125.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -73.8% | -135.2% | -90.1% | -86.5% | -32.6% | -74.1% |
| Return on equity | 529.1% | -2599.1% | -131.0% | -168.9% | -50.0% | -186.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.23 | 1.03 | 3.19 | 1.92 | 3.58 | 2.44 |
| Quick ratio | 1.22 | 1.03 | 3.19 | 1.92 | 3.58 | 2.41 |
| Cash ratio | 0.37 | 0.98 | 2.37 | 1.68 | 1.58 | 1.41 |
| Leverage | ||||||
| Debt / Equity | -2.73 | 12.58 | 0.00 | 0.19 | 0.16 | 0.62 |
| Debt / Assets | 0.38 | 0.65 | 0.00 | 0.10 | 0.10 | 0.25 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -6.1x | -39.5x | -93.5x | -40.6x | -27.2x | -21.1x |
| Equity multiplier | -7.16 | 19.23 | 1.45 | 1.95 | 1.53 | 2.52 |
| Liabilities / Assets | 1.14 | 0.95 | 0.31 | 0.61 | 0.41 | 0.71 |
| Efficiency | ||||||
| Asset turnover | 0.00 | - | 0.00 | 0.07 | 0.28 | 0.46 |
| Inventory turnover | 0.00 | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 0d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | 4510d | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | -100.0% | -86.7% | 0.0% | -56.2% |
| Revenue CAGR (3y) | - | - | - | -61.2% | 16.0% | - |
| Revenue CAGR (5y) | - | - | - | - | -6.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 16.3% | -99.6% | -17.3% | -23.7% | 16.8% | 19.6% |
| Net income growth (YoY) | 5.0% | -86.7% | -31.1% | -36.5% | 27.9% | 21.8% |
| EPS growth (YoY) | -9.5% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -101.1% | -51.8% | 30.2% | 48.1% | 0.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -90.6% | 69.0% | -59.6% | 169.1% | 63.8% |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-18.86
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CTI BIOPHARMA CORP against the 5 most active filers in the same SIC group.